Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Durvalumab + Guadecitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 65||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Guadecitabine||S110|DNMT inhibitor SGI-110||DNMT inhibitor (Pan) 5||Guadecitabine (SGI-110) is a dinucleotide comprised of decitabine and deoxyguanosine, which inhibits DNA methylation, potentially resulting in decreased tumor cell growth (PMID: 20442312, PMID: 17616700, PMID: 32655143).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03308396||Phase Ib/II||Durvalumab + Guadecitabine Guadecitabine||Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer||Recruiting|
|NCT03257761||Phase I||Durvalumab + Guadecitabine||Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer||Recruiting|